James Costello, PhD, University of Colorado Anschutz Medical Campus (IMAGE)

University of Colorado Anschutz Medical Campus

James Costello, PhD, University of Colorado Anschutz Medical Campus

Caption

James Costello, PhD, and colleagues report results of an NCI DREAM challenge predicting which prostate cancer patients will discontinue docetaxel due to adverse events.

Credit

University of Colorado Cancer Center

Usage Restrictions

With attribution

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.